Compare Merck & Co., Inc. (MRK) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Toronto-Dominion Bank — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while Toronto-Dominion Bank trades at $114.14 (market cap $185.79B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Toronto-Dominion Bank pays the higher dividend (2.84%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Toronto-Dominion Bank for 84 Days on average.
| MRK | TD | |
|---|---|---|
Market Cap | $351.28B | $185.79B |
Volume | 7,969,665 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $156.43 | $124.80 |
52-Week Low | $82.49 | $78.32 |
Typical Hold Time | 98 Days | 84 Days |
Enterprise Value | $398.04B | $559.06B |
Dividend Yield | 2.39% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
TD stock trades at $113.87, down 3.65% on the day, with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.98 exceeding expectations by 13.8%. Recent developments include a $10 billion share buyback program and a $108 billion commitment to Canadian infrastructure. Analyst consensus remains positive with 53% buy ratings and no sell recommendations.
TD presents a mixed investment case with strong profitability metrics (24.9% net margin, 13.6% ROE) offset by bearish technical indicators and volatile cash flow patterns. The stock's current valuation at 17.4x P/E appears reasonable given earnings growth, while the aggressive capital return program signals management confidence. Key risks include interest rate sensitivity and ongoing AML remediation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
